PharmaCyte Biotech Inc (PMCB)

[AJ_invest]

SILVER SPRING, Md., July 14, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the U.S. Patent and Trademark Office (USPTO) has granted patent protection of the Melligen cells that are a part of PharmaCyte’s therapy for Type 1 and insulin-dependent Type 2 diabetes.

The Melligen cells are human cells that have been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the body. PharmaCyte has the exclusive worldwide license from the University of Technology Sydney (UTS) to use these cells to develop a therapy for Type 1 and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Box® technology to function as an “artificial pancreas” for purposes of insulin production.

more